Impact of Sodium Glucose Cotransporter 2 Inhibitors on Weight in Patients With Type 2 Diabetes Mellitus

References

• . Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–321
   PubMed Web of Science ®Google Scholar
• . Cheng D. Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond). 2005;2:29
   PubMedGoogle Scholar
• . Gregg EW, Cheng YJ, Narayan KM, Thompson TJ, Williamson DF. The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976–2004. Prev Med. 2007;45(5):348–352
   PubMedGoogle Scholar
• . Bailey CJ. The challenge of managing coexistent type 2 diabetes and obesity. BMJ. 2011;342:d1996. doi:10.1136/bmj.d1996
   PubMedGoogle Scholar
• . Eckel RH, Kahn SE, Ferrannini E, . Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011;96(6):1654–1663
   PubMed Web of Science ®Google Scholar
• . World Health Organization. Fact sheet N°311. Obesity and overweight. May 2012 http://www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed February 5, 2013
   Google Scholar
• . Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–846
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstahl RM, Buse JB, . Management of hyperglycemia in type 2 diabetes: A patient centered approach. Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006;82(966):280–284
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetes—United States, 1988–1994 and 1999–2002. MMWR Morb Mortal Wkly Rep. 2004;53(45):1066–1068
   PubMedGoogle Scholar
• . WHO Expert Consultation. Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–163
   PubMed Web of Science ®Google Scholar
• . Low S, Chin MC, Ma S, Heng D, Deurenberg-Yap M. Rationale for redefining obesity in Asians. Ann Acad Med Singapore. 2009;38(1):66–69
   PubMed Web of Science ®Google Scholar
• . World Health Organization Western Pacific Region, International Association for the Study of Obesity, International Obesity Task Force. Redefining obesity and its treatment. 2000. http://www.wpro.who.int/nutrition/documents/docs/Redefiningobesity.pdf Accessed July 1, 2013
   Google Scholar
• . Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ. Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab. 2012;14(5):424–432
   PubMed Web of Science ®Google Scholar
• . Kramer H, Cao G, Dugas L, Luke A, Cooper R, Durazo-Arvizu R. Increasing BMI and waist circumference and prevalence of obesity among adults with type 2 diabetes: the National Health and Nutrition Examination Surveys. J Diabetes Complications. 2010;24(6):368–374
   PubMedGoogle Scholar
• . Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB Sr. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care. 2008;31(8):1582–1584
   PubMed Web of Science ®Google Scholar
• . Eeg-Olofsson K, Cederholm J, Nilsson PM, . Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52(1):65–73
   PubMed Web of Science ®Google Scholar
• . Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care. 1997;20(11):1744–1766
   PubMed Web of Science ®Google Scholar
• . Yki-Järvinen H, Ryysy L, Kauppila M, . Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82(12):4037–4043
   PubMed Web of Science ®Google Scholar
• . McEwan P, Evans M, Kan H, Bergenheim K. Understanding the interrelationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab. 2010;12(5):431–436
   PubMedGoogle Scholar
• . Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(3):186–194
   PubMedGoogle Scholar
• . Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23(10):1499–1504
   PubMed Web of Science ®Google Scholar
• . Norris SL, Zhang X, Avenell A, . Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev. 2005;(2):CD004095
   Google Scholar
• . Orlistat [prescribing information]. South San Francisco, CA: Genetech, Inc.; 2012. http://www.gene.com/gene/products/information/xenical/pdf/pi.pdf Accessed July 1, 2013
   Google Scholar
• . Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(1):CD004096
   Google Scholar
• . Greenway F. Obesity medications and the treatment of type 2 diabetes. Diabetes Technol Ther. 1999;1(3):277–287
   PubMedGoogle Scholar
• . Buchwald H, Avidor Y, Braunwald E, . Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–1737
   PubMed Web of Science ®Google Scholar
• . Sjöström L, Narbro K, Sjöström CD, . Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–752
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes–2012. Diabetes Care. 2012;35( Suppl 1):S11–S63
   PubMed Web of Science ®Google Scholar
• . Dixon JB, Zimmet P, Alberti KG, Rubino F; International Diabetes Federation Taskforce on Epidemiology and Prevention. Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med. 2011;28(6):628–642
   PubMed Web of Science ®Google Scholar
• . Feldstein AC, Nichols GA, Smith DH, . Weight change in diabetes and glycemic and blood pressure control. Diabetes Care. 2008;31(10):1960–1965
   PubMedGoogle Scholar
• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52(1):17–30
   PubMed Web of Science ®Google Scholar
• . Lind M. Incretin therapy and its effect on body weight in patients with diabetes. Prim Care Diabetes. 2012;6(3):187–191
   PubMedGoogle Scholar
• . Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369
   PubMed Web of Science ®Google Scholar
• . Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303(14):1410–1418
   PubMed Web of Science ®Google Scholar
• . National Council on Patient Information and Education. Enhancing Prescription Medicine Adherence: A National Action Plan. Bethesda, MD: National Council on Patient Information and Education; 2007. http://www.intelecare.com/downloads/ncpie-adherence-report.pdf Accessed August 2, 2013
   Google Scholar
• . Guidelines from the Case Management Society of America for improving patient adherence to medication therapies (2006). http://www.cmsa.org/portals/0/pdf/cmag2.pdf Accessed July 1, 2013
   Google Scholar
• . Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3):314–322
   PubMed Web of Science ®Google Scholar
• . Rubin RR, Peyrot M, Siminerio LM. Health care and patient-reported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2006;29(6):1249–1255
   PubMed Web of Science ®Google Scholar
• . Voorham J, Haaijer-Ruskamp FM, Wolffenbuttel BH, Stolk RP, Denig P; Groningen Initiative to Analyze Type 2 Diabetes Treatment Group. Medication adherence affects treatment modifications in patients with type 2 diabetes. Clin Ther. 2011;33(1):121–134
   PubMedGoogle Scholar
• . Currie CJ, Peyrot M, Morgan CL, . The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279–1284
   PubMed Web of Science ®Google Scholar
• . Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26(5):1408–1412
   PubMed Web of Science ®Google Scholar
• . Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416–424
   PubMed Web of Science ®Google Scholar
• . Marrett E, Stargardt T, Mavros P, Alexander CM. Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes Obes Metab. 2009;11(12):1138–1144
   PubMed Web of Science ®Google Scholar
• . Bøgelund M, Vilsbøll T, Faber J, Henriksen JE, Gjesing RP, Lammert M. Patient preferences for diabetes management among people with type 2 diabetes in Denmark: a discrete choice experiment. Curr Med Res Opin. 2011;27(11):2175–2183
   PubMed Web of Science ®Google Scholar
• . Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–142
   PubMed Web of Science ®Google Scholar
• . Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011;(120):S1–S6
   Google Scholar
• . DeFronzo RA, Davidson JA, del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5–14
   PubMed Web of Science ®Google Scholar
• . Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427–3434
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Hompesch M, Kasichayanula S, . Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes [Epub ahead of print, June 4, 2013]. Diabetes Care, doi:10.2337/dc13–0387
   Google Scholar
• . Devineni D, Morrow L, Hompesch M, . Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6):539–545
   PubMed Web of Science ®Google Scholar
• . Liu JJ, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? Diabetes. 2012;61 (9):2199–2204
   PubMed Web of Science ®Google Scholar
• . Bailey CJ, Iqbal N, T'joen C, List JF. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14(10):951–959
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–2224
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle H. A phase IIb, randomised, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):721–728
   PubMed Web of Science ®Google Scholar
• . Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012(5);66:446–456
   PubMed Web of Science ®Google Scholar
• . Kadowaki T, Ikeda S, Takano Y, . Tofogliflozin, a novel and selective SGLT2 inhibitor improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled on stable metformin or diet and exercise alone. Diabetes. 2012;61( Suppl 1):A22 [80-OR]
   Web of Science ®Google Scholar
• . Kawano H, Kashiwagi A, Kazuta K, Yoshida S, Ueyama E, Utsuno A. Long-term safety, tolerability and efficacy of ipragliflozin in Japanese patients with type 2 diabetes mellitus: IGNITE. Diabetes. 2012;61( Suppl 1):A611[2422-PO]
   Google Scholar
• . List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–657
   PubMed Web of Science ®Google Scholar
• . Polidori D, Zhao Y, Alba M, Ferrannini E. Treatment with canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, for 26 weeks improves indices of beta-cell function (BCF). Diabetes. 2012;61( Suppl 1):A265[1032-P]
   PubMedGoogle Scholar
• . Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13(12):1219–1227
   PubMed Web of Science ®Google Scholar
• . Seino Y, Sasaki T, Fukatsu A, Samukawa Y, Sakai S, Watanabe T. Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus. Diabetes. 2012;61( Suppl 1):A266–7[1039-P]
   Web of Science ®Google Scholar
• . Stenlöf K, Cefalu WT, Kim KA, . Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–382
   PubMed Web of Science ®Google Scholar
• . Woerle HJ, Ferrannini E, Berk A, Manun'Ebo M, Pinnetti S, Broedl UC. Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes. Diabetes. 2012;61( Suppl 1 A):LB13 [49-LB]
   Web of Science ®Google Scholar
• . Fonseca VA Ferrannini E, Wilding JP, . Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications. 2013;27(3):268–273
   PubMed Web of Science ®Google Scholar
• . Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes:a randomized, double-blind, placebo-controlled, 12-week study [Epub ahead of print, June 19, 2013]. Diabetes Obes Metab. doi:10.1111/dom.12149
   Google Scholar
• . Kashiwagi A Takinami Y, Kazuta K, Yoshida S, Utsuno A Nagase I. Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study. Diabetologia. 2011;54( Suppl 1):S68
   Google Scholar
• . Bailey CJ, Gross JL, Pieters A, Bastien A List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–2233
   PubMed Web of Science ®Google Scholar
• . Cefalu WT, Leiter LA, Niskanen L, . Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin. Diabetes. 2012;61( Suppl 1 A):LB10 [38-LB]
   Google Scholar
• . Bolinder J, Ljunggren Ö, Kullberg J, . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–1031
   PubMed Web of Science ®Google Scholar
• . Goto K, Kashiwagi A, Kazuta K, Yoshida S, Ueyama E, Utsuno A. Ipragliflozin reduces A1c and body weight in type 2 diabetes patients who have inadequate glycemic control on metformin alone: ILLUMINATE study. Diabetes. 2012;61( Suppl 1):A269[1046-P]
   Google Scholar
• . Nauck MA, del Prato S, Meier JJ, . Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: arandomized, 52-week, double-blind, active-controlled non-inferiority trial. Diabetes Care. 2011;34(9):2015–2022
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Jelaska A, Seman L, Pinnetti S, Hantel S, Woerle HJ. Efficacy and safety of BI 10773, a new sodium-glucose cotransporter-2 (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin. Diabetes. 2011;60:A271 [989-P]
   Web of Science ®Google Scholar
• . Rosenstock J, Aggarwal N, Polidori D, . Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232–1238
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15(5):403–409
   PubMed Web of Science ®Google Scholar
• . Schernthaner G, Gross JL, Rosenstock J, . Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial [published online ahead of print April 5, 2013]. Diabetes Care. doi:10.2337/dc12–2491
   Google Scholar
• . Wilding JP, Mathieu C, Vercruysse F, Usiskin K, Deng L, Canovatchel W. Canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes (T2D) inadequately controlled with metformin (MET) and sulfonylurea (SU). Diabetes. 2012;61( Suppl 1):A262 [1022-P]
   Web of Science ®Google Scholar
• . Haering HU, Merker L, Seewaldt-Becker E, . Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care, (in press)
   Google Scholar
• . Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473–1478
   PubMed Web of Science ®Google Scholar
• . Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928–938
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Woo V, Soler NG, . Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–415
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656–1662
   PubMed Web of Science ®Google Scholar
• . Forxiga [Summary of Product Characteristics]; 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/002322/WC500136026.pdf Accessed July 1, 2013
   Google Scholar
• . Invokana [full prescribing information]; 2013. http://www.janssenmd.com/pdf/invokana/PI-INVOKANA.pdf Accessed July 1, 2013
   Google Scholar
• . Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for investigational Type 2 Diabetes treatment empagliflozin. Boehringer-Ingelheim news release; March 2, 2013. http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/26_march_2013_empagliflozin.html. Accessed July 9, 2013
   Google Scholar
• . Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878–884
   PubMed Web of Science ®Google Scholar